"The U.S. Food and Drug Administration today approved Cometriq (cabozantinib) to treat medullary thyroid cancer that has spread to other parts of the body (metastasized).
Medullary thyroid cancer develops in cells in the thyroid gland that m"...
Patients being treated with Valtropin (somatropin injection) ® (and/or their parents) should be informed about the potential benefits and risks associated with Valtropin (somatropin injection) ® treatment. This information is intended to better educate patients (and caregivers); it is not a disclosure of all possible adverse or intended effects.
Patients and caregivers who will administer Valtropin (somatropin injection) ® should receive appropriate training and instruction on the proper use of Valtropin (somatropin injection) ® from the physician or other suitably qualified health care professional. A puncture-resistant container for the disposal of used syringes and needles should be strongly recommended. Patients and/or parents should be thoroughly instructed in the importance of proper disposal, and cautioned against any reuse of needles and syringes. This information is intended to aid in the safe and effective administration of the medication.
Last reviewed on RxList: 4/30/2007
This monograph has been modified to include the generic and brand name in many instances.
Additional Valtropin Information
Report Problems to the Food and Drug Administration
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.
Find out what women really need.